This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Rethinking Bipolar Depression

Rethinking Bipolar Depression

Format

Webcast

Time to Complete

30 minutes

Released

February 8, 2016

Expires

January 15, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM
0.50 / CE for Pharmacists (0.05 CEUs)

Accredited Provider


This educational initiative is provided by CME Outfitters.

Commercial Supporter

This educational activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc.

Program Description

Bipolar disorder is a frequent and clinically complex psychiatric disorder. Patients with bipolar disorder are exceptionally challenging to manage because of the dynamic, chronic, and fluctuating nature of their disease. The manic presentation of bipolar disorder in adults has received more attention, and treatment options are numerous while the depressive symptoms continue to be misdiagnosed and at present, there are only three FDA-approved treatments for bipolar depression. The use of screening tools in both psychiatry and primary care are underutilized and can assist in diagnosing bipolar depression and monitoring symptoms over time.1

Newer pharmacological agents used to treat the various clinical presentations of bipolar disorder generally offer efficacy with an improved side effect profile over the older second-generation antipsychotics. Clinicians need to keep up-to-date on the pharmacological profiles and safety and efficacy data on all of the recent agents for bipolar disorder.

In this neuroscienceCME Snack, the faculty will analyze and review treatment options for bipolar depression to offer clinicians the optimal, real-world context needed to combine the latest science with best practice to improve outcomes in patients with bipolar depression.

________________________________________

Reference
1. McIntyre RS, Correll C. Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disord. 2014;16(5):451-454. PMID: 25090934.

Intended Audience

Physicians, pharmacists, and other health care professionals with an interest in mood disorders

Educational Objectives

At the end of this CME/CE activity, participants should be able to:

  • Integrate evidence-based, best-practice options for the pharmacological management of patients with bipolar disorder
  • Implement a treatment plan in collaboration with patients with bipolar depression that differentiates the long-term metabolic impact of treatment choices

Conflict Of Interest Disclosure Policy

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Charles B. Nemeroff, MD, PhD
Leonard M. Miller Professor and Chairman
Director, Center on Aging
Department of Psychiatry and Behavioral Sciences
Leonard M. Miller School of Medicine
University of Miami
Miami, FL

Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Joseph R. Calabrese, MD
Bipolar Disorders Research Chair and Professor of Psychiatry
Case Western Reserve University School of Medicine
Director, Mood Disorders Program
University Hospitals Case Medical Center
Cleveland, OH

Dr. Calabrese has no disclosures to report.

Mark A. Frye, MD
Chair, Department of Psychiatry & Psychology
Professor of Psychiatry
Director, Integrated Mood Group
Mayo Clinic
Rochester, MN

Dr. Frye has disclosed that he received grant/research support from AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for Medical Education and Research; Myriad Genetics; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); and Pfizer Inc. He serves as a consultant for Janssen Research & Development, LLC; Mitsubishi Tanabe Pharma Corporation; Myriad Genetics; Neuralstem Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceuticals USA. He received CME/travel support from American Physician Institute and CME Outfitters, LLC. Mayo Clinic has a financial interest in AssureRX and the technology referenced in this publication/presentation.

Accredited Provider Disclosure

The CME Outfitters, LLC staff has nothing to disclose.

Planners' and Managers' Disclosures

Tony Graham, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

CME Outfitters designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.50 contact hours (0.05 CEUs)

Universal Activity Number: 0376-0000-16-014-H01-P

Activity Type: knowledge-based

Disclosure of Unlabeled Use

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.

To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact info@cmeoutfitters.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue